1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.3.1 Speculative Aspects of Assessing the Stem Cell Field
2. Introduction to Stem Cell Technologies
2.1 What Are Stem Cells?
2.2 How Are Stem Cells Classified?
2.2.1 Totipotency
2.2.2 Pluripotency
2.2.3 Multipotency
2.2.4 Oligopotency
2.2.5 Unipotency
2.3 Where Do Stem Cells Come From?
2.3.1 Embryonic Stem Cells
2.3.1.1 Abortion Debates, IVF and Embryonic Stem Cells
2.3.1.2 Harvesting Human Eggs
2.3.2 Adult Stem Cells
2.3.3 Umbilical Cord Blood Stem Cells
3. The Global Stem Cells Market 2011-2021
3.1 Defining the Stem Cells Market
3.2 Growth in the Stem Cells Market 2011-2021
3.3 Stem Cell Therapies
3.3.1 Stem Cell Therapies Market Forecast 2011-2021
3.3.2 Stem Cells and Bone Regeneration
3.3.2.1 Osteocel Plus (NuVasive)
3.3.2.2 Osteocel Plus Sales Forecast 2011-2021
3.3.2.3 Other Orthopaedic Stem Cell Products
3.3.3 Stem Cells and Regenerative Medicine
3.3.4 Stem Cell Cosmetics
3.3.5 Unregulated Stem Cell Therapies
3.4 Bone Marrow Transplants
3.4.1 Graft-versus-Host Disease and Host-versus-Graft Disease
3.4.2 Bone Marrow Transplants and Medicare Coverage
3.4.3 Private Bone Marrow Transplant Forecast 2011-2021
3.4.4 Peripheral Blood Stem Cell Transplants
3.4.5 Cord Blood Stem Cell Transplants
3.5 Stem Cell Services
3.5.1 Disease Modelling
3.5.2 Toxicity Screening
3.5.3 Stem Cell Services Market Forecast 2011-2021
3.6 Blood Banking
3.6.1 Private vs. Public Blood Banks
3.6.2 Arguments For and Against Cord Blood Banking
3.6.3 Private Cord Blood Banking Market Forecast 2011-2021
4. Companies Driving the Stem Cells Market
4.1 Leading Companies Developing Stem Cell Therapies
4.1.1 Aastrom Biosciences
4.1.2 Advanced Cell Technology
4.1.3 AmStem
4.1.4 Athersys
4.1.5 BioHeart
4.1.6 BrainStorm Cell Therapeutics
4.1.7 Cytori Therapeutics
4.1.8 Gamida Cell
4.1.9 Geron
4.1.9.1 Geron and GE Healthcare
4.1.10 MediStem Laboratories
4.1.11 Mesoblast
4.1.12 Neostem
4.1.13 Neuralstem
4.1.14 Opexa Therapeutics
4.1.14.1 Tovaxin
4.1.15 Osiris Therapeutics
4.1.15.1 Prochymal
4.1.15.2 Chondrogen
4.1.16 Pluristem Therapeutics
4.1.17 Reliance Life Sciences
4.1.18 ReNeuron
4.1.19 StemCells
4.1.20 TCA Cellular Therapy
4.2 Some Companies Offering Stem Cell Services
4.2.1 Axiogenesis
4.2.2 BioTime
4.2.2.1 CellCure Neurosciences
4.2.3 CellCyte Genetics
4.2.4 Cellular Dynamics International
4.2.5 International Stem Cell Corp
4.2.6 MultiCell Technologies
4.2.7 Regenetech
4.2.8 Stem Cell Innovations
4.2.9 Stemgent
4.2.10 Thermo Fisher Scientific/HyClone
4.2.11 ViaCyte
4.2.12 Vitro Biopharma
4.3 Selected Private Cord Blood Banks
4.3.1 Biogenea-Cellgenea
4.3.2 China Cord Blood Corp
4.3.3 Cord Blood America
4.3.4 Cryo-Cell International
4.3.5 Cryo-Save
4.3.6 LifebankUSA
4.3.7 Thermogenesis
4.3.8 ViaCord
5. Issues Affecting the Stem Cell Technologies Market 2011-2021
5.1 SWOT Chart for the Stem Cells Market 2011-2021
5.2 Strengths
5.2.1 Stem Cell Therapies Already Have a Number of Applications
5.2.2 Stem Cells Have Vast Therapeutic Potential
5.2.3 Stem Cells Have Uses Beyond Therapy
5.2.4 Strength in Numbers
5.2.5 Strong Government Support for Stem Cells
5.3 Weaknesses
5.3.1 The Research Field is Fragmented
5.3.2 A Complex Intellectual Property Environment
5.3.3 Research Relies Too Heavily on Government Funding
5.3.4 Difficulties in Scaling Up
5.3.5 Neither Autologous nor Allogeneic Therapies Are Perfect Yet
5.3.5.1 Autologous Therapies
5.3.5.2 Allogeneic Therapies
5.3.5.3 Incompatibility with the Existing Pharmaceutical Model?
5.4 Opportunities
5.4.1 Leading Pharma Companies Investing in Stem Cell Research
5.4.2 The Potential of iPSCs
5.4.2.1 Transdifferentiation
5.4.3 Philanthropy May Prove a Good Source of Funding
5.4.4 Asia Offers Dynamic Opportunities
5.4.4.1 South Korea
5.4.4.2 Israel
5.4.5 The First New Therapies Launched Will Drive Market Growth
5.5 Threats
5.5.1 Some Companies Will Fail
5.5.1.1 Case Study: Garnet BioTherapeutics
5.5.2 Maintaining Public Support is Vital but Difficult
5.5.3 Difficulties with Animal Models
5.5.4 There Remains Uncertainty in the Future Pathway of US Research
5.5.5 Rapid Progress Makes Certain Discoveries Obsolete
6. Therapeutic Applications for Stem Cell Therapies 2011-2021
6.1 Near-Term Indications
6.1.1 Cancer
6.1.1.1 Cancer Stem Cells
6.1.2 Immune Disorders
6.1.3 Eye Diseases
6.1.4 Orthopaedics
6.1.5 Diabetes
6.2 Cardiovascular Diseases
6.3 Central Nervous System (CNS) Diseases
6.3.1 Amyotrophic Lateral Sclerosis (ALS)
6.3.2 Multiple Sclerosis
6.3.2.1 Pelizaeus-Merzbacher Disease (PMD)
6.3.3 Alzheimer's Disease
6.3.4 Cerebral Palsy
6.3.5 Parkinson's Disease
6.3.6 Spinal Cord Injury
6.4 Growing Organs
7. Regional Analysis of the Stem Cells Market 2011-2021
7.1 Global Spread of Stem Cell Research
7.2 The United States
7.2.1 US Market Drivers and Restraints, 2011-2021
7.2.2 California Institute of Regenerative Medicine (CIRM)
7.3 Japan
7.3.1 Commercial Aspects of Stem Cells in Japan
7.4 Europe
7.4.1 The UK
7.4.2 Spain
7.4.3 Germany
7.4.4 France
7.4.5 Italy
7.5 China
7.6 India
8. Research Interview
8.1 Yael Margolin, President and CEO, Gamida Cell
8.1.1 Challenges in Developing Stem Cell Therapies
8.1.2 Israel's Strength in Stem Cell Research
8.1.3 Public Perception of Stem Cell Therapies
8.1.4 Therapeutic Targets and Gamida Cell's Stem Cell Therapies
8.1.5 Umbilical Cord Blood Stem Cells
9. Conclusions
9.1The Stem Cells Market is Currently Small
9.2 Market Growth Will be Dependent on Stem Cell Therapies
9.3 Induced Pluripotent Stem Cells Represent a Strong Market Opportunity
9.4 Stem Cell Therapies Will be Used in Many Disease Areas
9.5 Concluding Remarks
List of Tables
Table 1.1 Currency Exchange Rates, 2009-2010
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
Table 3.1 Global Stem Cell Market, 2010
Table 3.2 Global Stem Cells Market: Forecast, 2010-2021
Table 3.3 Global Stem Cells Market: Drivers and Restraints, 2011-2021
Table 3.4 Selected Uses for Stem Cells Therapies, 2011
Table 3.5 Stem Cell Therapies Market: Drivers and Restraints, 2011-2021
Table 3.6 Osteocel Plus Sales Forecast, 2010-2021
Table 3.7 Companies Not Considered Part of the Stem Cell Market in this Report
Table 3.8 Sources of Stem Cells for Bone Marrow Transplants
Table 3.9 Medicare Coverage for Bone Marrow Transplants, 2011
Table 3.10 Bone Marrow Transplants Market: Drivers and Restraints, 2011-2021
Table 3.11 Stem Cell Services Market: Drivers and Restraints, 2011-2021
Table 3.12 Costs of Various Private Cord Blood Banks Worldwide, 2011
Table 3.13 Cord Blood Banking Market: Drivers and Restraints, 2011-2021
Table 4.1 Selected Stem Cell Therapy Companies and Their Leading Products, 2011
Table 4.2 Histostem's Leading Clinical Investigations, 2011
Table 4.3 MultiStem Pipeline, 2011
Table 4.4 Gamida Cell's Stem Cell Therapy Pipeline, 2011
Table 4.5 Geron's Stem Cell Therapy Pipeline, 2011
Table 4.6 Clinical Progress of GRN-1632, 2011
Table 4.7 Osiris Therapeutics Stem Cell Pipeline, December 2010
Table 4.8 TCA Cellular Therapy Clinical Progress, 2011
Table 4.9 Selected Stem Cell Services Companies, 2011
Table 4.10 Selected Private Cord Blood Banks, 2011
Table 4.11 China Cord Blood Corp Revenue and Subscribers, 2009-2010
Table 4.12 Cryo-Cell International Revenue, 2009-2010
Table 4.13 Cryo-Save Revenue and Operating Profit, 2009-2010
Table 4.14 Cryo-Save Revenue by Region, 2010
Table 5.1 SWOT Analysis of the Market, 2011-2021
Table 5.2 NIH Human Stem Cell Research Funding, 2002-2010
Table 6.1 Selected Examples of Stem Cell Research, 2010-2011
Table 6.2 Stem Cell Clinical Trials by Indication, 2011
Table 6.3 Neurodegenerative Diseases: Stem Cell Clinical Trials by Indication, 2011
Table 7.1 Stem Cell Clinical Trials by Country, 2011
Table 7.2 NIH Stem Cell Research Funding, 2002-2010
Table 7.3 CIRM Funding by Disease, 2004-2011
Table 7.4 Indian Stem Cell Clinical Trials Conducted, 2011
Table 9.1 Stem Cells Market Value and Market Shares, 2010, 2016 and 2021
List of Figures
Figure 2.1 The Early History of Stem Cell Discovery and Development
Figure 3.1 Global Stem Cell Market, 2010
Figure 3.2 Global Stem Cells Market Forecast, 2010-2021
Figure 3.3 Stem Cell Therapies Market Forecast, 2010-2021
Figure 3.4 Osteocel Plus Sales Forecast, 2010-2021
Figure 3.5 Private Bone Marrow Transplant Market Forecast, 2011-2021
Figure 3.6 Stem Cell Services Market Forecast, 2010-2021
Figure 3.7 Twenty Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
Figure 3.8 Cord Blood Banking Market Forecast, 2010-2021
Figure 4.1 MultiStem Key Events, 2006-2011
Figure 4.2 China Cord Blood Corp Revenue and Subscribers, 2009-2010
Figure 4.3 Cryo-Cell International Revenue, 2009-2010
Figure 4.4 Cryo-Save Revenue and Operating Profit, 2009-2010
Figure 4.5 Cryo-Save Revenue by Region, 2010
Figure 5.1 NIH Human Stem Cell Research Funding, 2002-2010
Figure 5.2 Pfizer's Stem Cell Collaborations, 2008-2011
Figure 6.1 Stem Cell Clinical Trials for Cancer by Phase, 2011
Figure 6.2 Neurodegenerative Diseases: Stem Cell Clinical Trials by Indication, 2011
Figure 6.3 Five Stages of Parkinson's Disease
Figure 7.1 Stem Cell Clinical Trials by Country, 2011
Figure 7.2 NIH Stem Cell Research Funding, 2002-2010
Figure 7.3 Key Events in the US Federal Funding of hESC Research Lawsuit, 2009-2010
Figure 7.4 CIRM Funding by Disease, 2004-2011
Figure 7.5 Example of the UK Stem Cell Therapy Regulatory Pathway, 2011
Figure 9.1 Stem Cells Market by Sector, 2016
Figure 9.2 Stem Cells Market by Sector, 2021